非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）：患病率、治疗创新及临床开发的障碍 - Suppr

Suppr

超能文献

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development.

作者信息

Alkhouri Naim

机构信息

Texas Liver Institute, University of Texas (UT) Health San Antonio, San Antonio, TX, USA.

出版信息

Expert Opin Investig Drugs. 2020 Feb;29(2):115-116. doi: 10.1080/13543784.2020.1721167. Epub 2020 Feb 3.

DOI:10.1080/13543784.2020.1721167

PMID:31971024

Abstract

摘要

相似文献

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development.

Expert Opin Investig Drugs. 2020 Feb;29(2):115-116. doi: 10.1080/13543784.2020.1721167. Epub 2020 Feb 3.

Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) - how are clinical trials affected?

Expert Opin Investig Drugs. 2020 Feb;29(2):93-97. doi: 10.1080/13543784.2020.1716333. Epub 2020 Jan 21.

[Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].

Yakugaku Zasshi. 2019;139(9):1147-1153. doi: 10.1248/yakushi.19-00011-1.

NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges.

Expert Opin Investig Drugs. 2020 Feb;29(2):87. doi: 10.1080/13543784.2020.1721169. Epub 2020 Jan 29.

Nonalcoholic Fatty Liver Disease.

Prim Care. 2017 Dec;44(4):599-607. doi: 10.1016/j.pop.2017.07.003.

Multi-drug approaches to NASH: what's in the development pipeline?

Expert Opin Investig Drugs. 2020 Feb;29(2):143-150. doi: 10.1080/13543784.2020.1668926. Epub 2019 Sep 23.

Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.

Contemp Clin Trials. 2017 Oct;61:33-38. doi: 10.1016/j.cct.2017.07.015. Epub 2017 Jul 19.

Prof Jörn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH).

Expert Opin Investig Drugs. 2020 Feb;29(2):111-113. doi: 10.1080/13543784.2020.1721150. Epub 2020 Feb 3.

Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?

Curr Vasc Pharmacol. 2018;16(3):269-275. doi: 10.2174/1570161115666170621082237.

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

J Gastroenterol. 2015 Apr;50(4):364-77. doi: 10.1007/s00535-015-1050-7. Epub 2015 Feb 24.

引用本文的文献

Inhibition of Extracellular Cathepsin D Reduces Hepatic Lipid Accumulation and Leads to Mild Changes in Inflammationin NASH Mice.

Front Immunol. 2021 Jul 16;12:675535. doi: 10.3389/fimmu.2021.675535. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development.

Expert Opin Investig Drugs. 2020 Feb;29(2):115-116. doi: 10.1080/13543784.2020.1721167. Epub 2020 Feb 3.

Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) - how are clinical trials affected?

Expert Opin Investig Drugs. 2020 Feb;29(2):93-97. doi: 10.1080/13543784.2020.1716333. Epub 2020 Jan 21.

[Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].

Yakugaku Zasshi. 2019;139(9):1147-1153. doi: 10.1248/yakushi.19-00011-1.

NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges.

Expert Opin Investig Drugs. 2020 Feb;29(2):87. doi: 10.1080/13543784.2020.1721169. Epub 2020 Jan 29.

Nonalcoholic Fatty Liver Disease.

Prim Care. 2017 Dec;44(4):599-607. doi: 10.1016/j.pop.2017.07.003.

Multi-drug approaches to NASH: what's in the development pipeline?

Expert Opin Investig Drugs. 2020 Feb;29(2):143-150. doi: 10.1080/13543784.2020.1668926. Epub 2019 Sep 23.

Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.

Contemp Clin Trials. 2017 Oct;61:33-38. doi: 10.1016/j.cct.2017.07.015. Epub 2017 Jul 19.

Prof Jörn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH).

Expert Opin Investig Drugs. 2020 Feb;29(2):111-113. doi: 10.1080/13543784.2020.1721150. Epub 2020 Feb 3.

Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?

Curr Vasc Pharmacol. 2018;16(3):269-275. doi: 10.2174/1570161115666170621082237.

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

J Gastroenterol. 2015 Apr;50(4):364-77. doi: 10.1007/s00535-015-1050-7. Epub 2015 Feb 24.

引用本文的文献

Inhibition of Extracellular Cathepsin D Reduces Hepatic Lipid Accumulation and Leads to Mild Changes in Inflammationin NASH Mice.

Front Immunol. 2021 Jul 16;12:675535. doi: 10.3389/fimmu.2021.675535. eCollection 2021.

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development.

作者信息

Alkhouri Naim

机构信息

Texas Liver Institute, University of Texas (UT) Health San Antonio, San Antonio, TX, USA.

出版信息

Expert Opin Investig Drugs. 2020 Feb;29(2):115-116. doi: 10.1080/13543784.2020.1721167. Epub 2020 Feb 3.

DOI:10.1080/13543784.2020.1721167

PMID:31971024

Abstract

摘要